Iisager, Laura
Ahrenfeldt, Johanne
Donskov, Frede
Ljungberg, Börje
Bex, Axel
Lund, Lars
Lyskjær, Iben
Fristrup, Niels
Funding for this research was provided by:
Lundbeck Foundation (R413-2022-606)
Kræftens Bekæmpelse (R352-A20516)
DCCC Danish Research Centre for circulating tumor DNA guided treatment (20230426_2)
Danmarks Frie Forskningsfond (2100-00017B)
The Danish Health Authority (05-0400-48)
Article History
Received: 1 February 2024
Accepted: 9 February 2024
First Online: 24 February 2024
Declarations
:
: The study is conducted according to the guidelines of the Declaration of Helsinki and approved by the Danish National Center for Ethics (1–10-72–158-19, version 2.0 approved 14–09-2023 l). The patient should be informed about the protocol prior to the diagnostic (routine) biopsy in order to have the fresh baseline biopsy to coincide with the diagnostic (routine) biopsy, thereby avoiding delay in systemic therapy initiation. It is the responsibility of the investigator, or a person designated by the investigator (if acceptable by local regulations), to obtain written informed consent from each patient participating in this study, after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. Patient information is collected and maintained in an Aarhus University controlled REDCap database by the project nurse and the responsible data manager.
: Not applicable.
: NF has performed consultancy for Pfizer, Eisai, MSD, BMS, and has received speaker honoraria from AstraZeneca, BMS, MSD. BL: Company speaker: Novartis, IPSEN, BMS; Company consultant: Janssen, Ipsen, MSD; Trial participation: Jenssen—Astellas – Medivation. AB: grants from Pfizer and steering committee membership of Roche and BMS, consultancy for IPSEN. The other authors declare no conflicts of interest.